PATENT COOPERATION TREATY

To: JOHN RICHARDS LADAS & PARRY LLP 26 WEST 61ST STREET			PCT							
NEW YORK,	NY 10023		WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY							
				(PCT Rule 43bis.1)						
			Date of mailing (day/month/year)	05 DEC 2005						
Applicant's or a	agent's file reference		FOR FURTHER	ACTION See paragraph 2 below						
International ap	plication No.	International filing date	(day/month/year)	Priority date (day/month/year)						
PCT/US05/135	94									
		21 April 2005 (21.04.20) or both national classifica	tion and IPC	26 April 2004 (26.04.2004)						
		.: 514/693, 706, 743; 424/7								
Applicant		51 11 025, 700, 745, 42477	10							
СОМОСОРНІІ	LIPS COMPANY									
1. This opinion	n contains indications r	elating to the following iten	ns:							
Box	No. I Basis of t	he opinion								
Box No. II Priority										
Box No. IV Lack of unity of invention Box No. V Reasoned statement under Rule 43 bis. 1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement										
						Box		cuments cited		
						Box No. VII Certain defects in the international application				
Box 1	No. VIII Certain ob	servations on the internation	nal application	d application						
2. FURTHER	RACTION									
Authority oth	ner than this one to be		DEA has make a does i	be considered to be a written opinion of the not apply where the applicant chooses as International Bureau under Rule 66.1bis(b) ed.						
		e, considered to be a writte e appropriate, with amendn expiration of 22 months fro		EA, the applicant is invited to submit to the tration of 3 months from the date of mailing thickever expires later.						
For further or	otions, see Form PCT/IS	SA/220.	pricing dute, w							
3. For further de	tails, see notes to Form	PCT/ISA/220.								
ame and mailing	address of the ISA/U	S Date of completi	on of this calaisa	uthorized officer						
Mail Stop PCT, Attn: ISA/US			•	Authorized officer January Stur						
P.O. Box	oner for Patents 1450 a, Virginia 22313-1450	13 November 20	05 (13.11.2005)	Sreeni Padmanabhan						

EXPRESS MAIL LABEL NO.: EV 815 586 059 US

Best Available Copy

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.	
)⊱`	
PCT/US05/13594·	

With .	regard to the language, this opinion has been established on the basis of:
	the international application in the language in which it was filed
	a translation of the international application into, which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).
	regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed tion, this opinion has been established on the basis of:
a.	type of material
	a sequence listing
	table(s) related to the sequence listing
b.	format of material
	on paper
	in electronic form
c.	time of filing/furnishing
	contained in the international application as filed.
	filed together with the international application in electronic form.
	furnished subsequently to this Authority for the purposes of search.
3.	In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
1. Addit	ional comments:
	·
	·
	·

Form PCT/ISA/237(Box No. I) (April 2005)

busi Available Cary

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International applic PCT/US05/13594

Box No. V Reasoned statement under Rule 43 bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement 1. Statement Novelty (N) Claims 42-64 Claims 1-41 No Inventive step (IS) Claims 42-64 Claims 1-41 No Industrial applicability (IA) Claims 1-64 Claims NONE Claims NONE 2. Citations and explanations: Claims 1-41 lack novelty under PCT Article 33(2) as being anticipated by Reinsel et al. Reinsel et al. discloses a method of inhibiting sulfide production by sulfate-reducing bacteria(SRB), wherein said method comprises contacting the SRB with a biocide glutaraldehyde, and metabolite inhibitor nitrite. See abstract; pages 134-135. The concentration of glutaraldehyde used was 0.1 mM, and intrite was 3.57 mM. Thus Reinsel anticipates instant claims 1-41. Claims 1-64 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claimed can be made or used in industry.			·
1. Statement Novelty (N) Claims 42-64 Claims 1-41 NO Inventive step (IS) Claims 42-64 Claims 1-41 NO Industrial applicability (IA) Claims 1-64 Claims NONE Claims 1-64 NO 2. Citations and explanations: Claims 1-41 lack novelty under PCT Article 33(2) as being anticipated by Reinsel et al. Reinsel et al. discloses a method of inhibiting sulfide production by sulfate-reducing bacteria(SRB), wherein said method comprises contacting the SRB with a biocide glutaraldehyde, and metabolite inhibitor nitrite. See abstract; pages 134-135. The concentration of glutaraldehyde used was 0.1 mM, and nitrite was 3.57 mM. Thus Reinsel anticipates instant claims 1-41. Claims 1-64 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claimed can			entive step or industrial
Novelty (N) Claims 42-64 Claims 1-41 NO Inventive step (IS) Claims 42-64 Claims 1-41 NO Industrial applicability (IA) Claims 1-64 Claims NONE NO 2. Citations and explanations: Claims 1-41 lack novelty under PCT Article 33(2) as being anticipated by Reinsel et al. Reinsel et al. discloses a method of inhibiting sulfide production by sulfate-reducing bacteria(SRB), wherein said method comprises contacting the SRB with a biocide glutaraldehyde, and metabolite inhibitor nitrite. See abstract; pages 134-135. The concentration of glutaraldehyde used was 0.1 mM, and nitrite was 3.57 mM. Thus Reinsel anticipates instant claims 1-41. Claims 1-64 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claimed can			
Inventive step (IS) Claims 1-41 Claims 42-64 Claims 1-41 NO Industrial applicability (IA) Claims 1-64 Claims NONE Claims NONE Claims NONE Claims 1-41 lack novelty under PCT Article 33(2) as being anticipated by Reinsel et al. Reinsel et al. discloses a method of inhibiting sulfide production by sulfate-reducing bacteria(SRB), wherein said method comprises contacting the SRB with a biocide glutaraldehyde, and metabolite inhibitor nitrite. See abstract; pages 134-135. The concentration of glutaraldehyde used was 0.1 mM, and nitrite was 3.57 mM. Thus Reinsel anticipates instant claims 1-41. Claims 1-64 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claimed can			VDO
Inventive step (IS) Claims 42-64 Claims 1-41 NO Industrial applicability (IA) Claims 1-64 Claims NONE Claims NONE Claims 1-64 Claims NONE Claims 1-41 lack novelty under PCT Article 33(2) as being anticipated by Reinsel et al. Reinsel et al. discloses a method of inhibiting sulfide production by sulfate-reducing bacteria(SRB), wherein said method comprises contacting the SRB with a biocide glutaraldehyde, and metabolite inhibitor nitrite. See abstract; pages 134-135. The concentration of glutaraldehyde used was 0.1 mM, and nitrite was 3.57 mM. Thus Reinsel anticipates instant claims 1-41. Claims 1-64 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claimed can	Novelty (N)		
Industrial applicability (IA) Claims 1-64 Claims 1-65 Claims 1-65 Claims 1-65 Claims 1-66		Claims 1-41	
Industrial applicability (IA) Claims 1-64	Inventive step (IS)	Claims <u>42-64</u>	YES
Claims NONENO 2. Citations and explanations: Claims 1-41 lack novelty under PCT Article 33(2) as being anticipated by Reinsel et al. Reinsel et al. discloses a method of inhibiting sulfide production by sulfate-reducing bacteria(SRB), wherein said method comprises contacting the SRB with a biocide glutaraldehyde, and metabolite inhibitor nitrite. See abstract; pages 134-135. The concentration of glutaraldehyde used was 0.1 mM, and nitrite was 3.57 mM. Thus Reinsel anticipates instant claims 1-41. Claims 1-64 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claimed can		Claims 1-41	NO
Claims NONENO 2. Citations and explanations: Claims 1-41 lack novelty under PCT Article 33(2) as being anticipated by Reinsel et al. Reinsel et al. discloses a method of inhibiting sulfide production by sulfate-reducing bacteria(SRB), wherein said method comprises contacting the SRB with a biocide glutaraldehyde, and metabolite inhibitor nitrite. See abstract; pages 134-135. The concentration of glutaraldehyde used was 0.1 mM, and nitrite was 3.57 mM. Thus Reinsel anticipates instant claims 1-41. Claims 1-64 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claimed can	Industrial applicability (IA)	Claims 1-64	YES
Claims 1-41 lack novelty under PCT Article 33(2) as being anticipated by Reinsel et al. Reinsel et al. discloses a method of inhibiting sulfide production by sulfate-reducing bacteria(SRB), wherein said method comprises contacting the SRB with a biocide glutaraldehyde, and metabolite inhibitor nitrite. See abstract; pages 134-135. The concentration of glutaraldehyde used was 0.1 mM, and nitrite was 3.57 mM. Thus Reinsel anticipates instant claims 1-41. Claims 1-64 meet the criteria set out in PCT Article 33(4), and thus have industrial applicability because the subject matter claimed can			
	Claims 1-41 lack novelty under PCT Article 33(2) a Reinsel et al. discloses a method of inhibiting sulfid contacting the SRB with a biocide glutaraldehyde, a glutaraldehyde used was 0.1 mM, and nitrite was 3. Thus Reinsel anticipates instant claims 1-41. Claims 1-64 meet the criteria set out in PCT Article	e production by sulfate-reducing bacteria(SRB), and metabolite inhibitor nitrite. See abstract; page 57 mM.	es 134-135. The concentration of
			•